DL-dihydrozeatin
CAS No. 14894-18-9
DL-dihydrozeatin( ——— )
Catalog No. M38672 CAS No. 14894-18-9
DL-dihydrozeatin
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | Get Quote | Get Quote |
|
| 50MG | Get Quote | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameDL-dihydrozeatin
-
NoteResearch use only, not for human use.
-
Brief DescriptionDL-dihydrozeatin
-
DescriptionDL-dihydrozeatin
-
In Vitro———
-
In Vivo———
-
Synonyms———
-
PathwayOthers
-
TargetOther Targets
-
Recptor———
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number14894-18-9
-
Formula Weight221.26
-
Molecular FormulaC10H15N5O
-
Purity>98% (HPLC)
-
Solubility———
-
SMILES———
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
GLP-1(7-37) acetate(...
Glp-1 (7-37)acetate is an intestinal insulin hormone that enhances glucose-induced insulin secretion.
-
trans-Isoferulic aci...
Isoferulic acid is an effective natural antioxidant in both lipid and aqueous media, it may be a new promising anti-glycation agent for the prevention of diabetic complications via inhibition of advanced glycation end products (AGEs) formation and oxidation-dependent protein damage.
-
Siplizumab
Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody that targets CD2, selectively depleting effector memory T cells and promoting the relative expansion of alloreactive regulatory T cells in vitro. Siplizumab can be used to treat plaque psoriasis.
Cart
sales@molnova.com